Urge incontinence, increased urinary frequency

Active Ingredient: Oxybutinin

Indication for Oxybutinin

Population group: only adults (18 years old or older)
Therapeutic intent: Curative procedure

Symptomatic treatment of urge incontinence and/or increased urinary frequency and urgency as may occur in adult patients with unstable bladder.

For this indication, competent medicine agencies globally authorize below treatments:

5-20 mg once daily


Route of admnistration


Defined daily dose

5 - 20 mg

Dosage regimen

From 5 To 20 mg once every day

Loading dose

5 mg

Maintenance dose

10 mg

Detailed description

Starting dose: the recommended starting dose is one 5 mg tablet once daily.

Maintenance dose/dose adjustment: In order to achieve a maintenance dose giving an optimal balance of efficacy and tolerability, after at least one week on 5 mg daily, the dose may be increased to 10 mg once daily, with subsequent incremental increases or decreases of 5 mg/day. There should be an interval of at least one week between dose changes.

Maximum dose: in patients requiring a higher dose, the total daily dose should not exceed 20 mg.

For patients currently taking oxybutynin immediate release, clinical judgement should be exercised in selecting the appropriate dose of oxybutynin. The dosage should be adjusted to the minimum dose that achieves an optimal balance of efficacy and tolerability, taking into account the current immediate-release dose.

In case of a missed dose, the patient should wait and take the next dose at the regular time.

Dosage considerations

Oxybutinin tablet must be swallowed whole with the aid of liquid, and must not be chewed, divided, or crushed because it is formulated to provide prolonged release.

Oxybutinin tablet may be administered with or without food.

3.9 mg twice weekly

Route of admnistration


Defined daily dose

3.9 - 3.9 mg

Dosage regimen

From 3.9 To 3.9 mg once every 3 day(s)

Detailed description

The recommended dose is one 3.9 mg transdermal patch applied twice weekly (every 3 to 4 days).


Based on clinical trial experience no dose adjustment is considered necessary in this population. Nonetheless oxybutynin transdermal patch should be used with caution in elderly patients, who may be more sensitive to the effects of centrally acting anticholinergics and exhibit differences in pharmacokinetics.

Dosage considerations

The patch should be applied to dry, intact skin on the abdomen, hip, or buttock immediately after removal from the protective sachet. A new application site should be selected with each new patch to avoid reapplication to the same site within 7 days.

Active ingredient


Oxybutynin acts as a competitive antagonist of acetylcholine at post-ganglionic muscarinic receptors, resulting in relaxation of bladder smooth muscle.

Read more about Oxybutinin

Related medicines

Develop a tailored medication plan for your case, considering factors such as age, gender, and health history

Ask the Reasoner

Liability Disclaimer : RxReasoner has utilized reasonable care in providing content and services that are accurate, complete and up to date. However, RxReasoner does not accept any responsibility or liability about it. The content and services of RxReasoner are for informational purposes only and they are not intended to be a substitute for the knowledge, expertise, skill, and judgment of physicians, pharmacists, nurses, or other healthcare professionals involved in patient care. RxReasoner offers no medical advice. Users are responsible for the use of the provided content. A shown indication or treatment should not be construed to indicate that the medication is safe, appropriate, or effective in any given patient or under any particular circumstances. The absence of an indication or treatment should not roule out the existence of other appropriate medications. Always seek the advice of a physician or other qualified health provider with any questions you may have regarding a medical condition or medicament. RxReasoner is not liable for any damages allegedly sustained arising out of the use of its content and services.